Scholarlink

Introduction <p>Herpes zoster (HZ) represents a significant health and economic burden in Vietnam, driven by direct medical costs and influenced by patient’s age, comorbidities, immunodeficiency, and HZ complications, including postherpetic neuralgia. This study was conducted to improve knowledge about the economic burden of HZ and associated costs in Vietnam.</p> Methods <p>A retrospective cost-of-illness study was conducted using medical chart records of patients with HZ who sought medical care in July 2022–June 2023 at six specialized dermatologic hospitals in Vietnam. Total direct medical costs of HZ management were calculated per patient and per hospital visit, and analyzed according to age, health insurance or out-of-pocket payment, complications, comorbidities, and immune status. Costs were collected in Vietnamese dong in 2023 and converted to 2023 US dollars. Direct nonmedical and indirect costs were estimated based on published studies.</p> Results <p>The study included 1828 patients. The mean direct medical costs of HZ treatment were $114 per patient and $92 per hospital visit. Direct medical costs were influenced by older age, presence of complications and comorbidities, and immunodeficiency. Mean direct nonmedical costs were $18 per patient and $14 per visit, and indirect costs were estimated at $104 per patient and $84 per visit. Direct costs were generally higher for inpatients than outpatients. Indirect costs were largely similar for inpatients and outpatients. Out-of-pocket payments contributed more towards direct medical costs than health insurance payments.</p> Conclusion <p>HZ and its complications impose a significant burden on patients and the private healthcare sector in Vietnam. Older age, comorbidities, immunodeficiency, and hospitalization were identified as key cost drivers in HZ management. The findings reflect the importance of introducing new management options to reduce the economic burden of HZ, and could support decision-making related to HZ prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Estimation of Costs Related to the Management of Herpes Zoster and its Complications in Vietnam: A Medical Chart Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Nurilign Ahmed,
  • Van M. Nguyen,
  • Anh C. Pham,
  • Nam H. Nguyen,
  • Minh Nguyen,
  • Son T. Tran,
  • Nguyen T. Tran,
  • Doanh H. Le,
  • Quyen T. L. Nguyen,
  • Nhan T. Nguyen,
  • Thanh D. Le,
  • Huong T. T. Nguyen

摘要

Introduction

Herpes zoster (HZ) represents a significant health and economic burden in Vietnam, driven by direct medical costs and influenced by patient’s age, comorbidities, immunodeficiency, and HZ complications, including postherpetic neuralgia. This study was conducted to improve knowledge about the economic burden of HZ and associated costs in Vietnam.

Methods

A retrospective cost-of-illness study was conducted using medical chart records of patients with HZ who sought medical care in July 2022–June 2023 at six specialized dermatologic hospitals in Vietnam. Total direct medical costs of HZ management were calculated per patient and per hospital visit, and analyzed according to age, health insurance or out-of-pocket payment, complications, comorbidities, and immune status. Costs were collected in Vietnamese dong in 2023 and converted to 2023 US dollars. Direct nonmedical and indirect costs were estimated based on published studies.

Results

The study included 1828 patients. The mean direct medical costs of HZ treatment were $114 per patient and $92 per hospital visit. Direct medical costs were influenced by older age, presence of complications and comorbidities, and immunodeficiency. Mean direct nonmedical costs were $18 per patient and $14 per visit, and indirect costs were estimated at $104 per patient and $84 per visit. Direct costs were generally higher for inpatients than outpatients. Indirect costs were largely similar for inpatients and outpatients. Out-of-pocket payments contributed more towards direct medical costs than health insurance payments.

Conclusion

HZ and its complications impose a significant burden on patients and the private healthcare sector in Vietnam. Older age, comorbidities, immunodeficiency, and hospitalization were identified as key cost drivers in HZ management. The findings reflect the importance of introducing new management options to reduce the economic burden of HZ, and could support decision-making related to HZ prevention.